Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Status:
Completed
Trial end date:
2021-02-12
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if chemotherapy given with rituximab,
followed by Ibritumomab tiuxetan (Zevalin), and then followed by rituximab can help to
control lymphoma. The safety of this treatment schedule will also be studied.
Objectives:
1. To assess whether the time to progression for these high-risk patients can be prolonged
to a median of 36 months, compared to the historical expectation of approximately 24
months.
2. To assess the tolerance and efficacy of Y2B8 (Zevalin) after R-FND (rituximab,
fludarabine, mitoxantrone, dexamethasone) in patients with high-risk stage III-IV
follicular lymphoma
3. To assess overall response, failure-free survival, and survival of this strategy
compared to our historical experience with FND (fludarabine, mitoxantrone,
dexamethasone) alone or R-FND
4. To assess the tolerance and efficacy of maintenance therapy with rituximab.
5. To maximize the 12-month molecular remission rate for patients with high-risk stage
III-IV follicular lymphoma
6. to correlate the results of quantitative PCR assay with classical PCR and with clinical
outcome